1 / 27

Phase 0 Trials Role in Radiation Mitigation Agent Development?

Phase 0 Trials Role in Radiation Mitigation Agent Development?. Anthony J. Murgo, M.D., M.S. Office of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration. Jan 25, 2010. Outline. Description of Phase 0 trials

media
Download Presentation

Phase 0 Trials Role in Radiation Mitigation Agent Development?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 0 TrialsRole in Radiation Mitigation Agent Development? Anthony J. Murgo, M.D., M.S. Office of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration Jan 25, 2010

  2. Outline • Description of Phase 0 trials • Phase 0 vs. traditional first-in-human Phase 1 trials • Types of agents appropriate for Phase 0 testing • Ways Phase 0 may improve efficiency of drug development

  3. Disclosure

  4. What is a Phase 0 trial? A what???

  5. What is a Phase 0 trial?

  6. Basic Features of Phase 0 trials • First-in-human trial conducted prior to traditional Phase 1 study • Small number of subjects (≈10-15) • Limited drug exposure • Low, non-toxic doses • Short duration (≈ ≤7 days) • One course only • No therapeutic intent • Phase 0 trials are not definitive studies

  7. Phase 0 trials can start earlier than Phase 1 Conceived under FDA’s “Critical Path” initiative to help sponsors identify promising candidate drugs more quickly Toxicology evaluation less extensive than for traditional IND because of reduced dosing and limited exposure.

  8. How do Phase 0 Trials Differ from Traditional First-In-Human Phase 1 Trials?

  9. Phase 0 vs. FIH Phase 1 Oncology Trials

  10. Phase 0 vs. FIH Phase 1 Oncology Trials

  11. Phase 0 vs. FIH Phase 1 Oncology Trials (cont.)

  12. Phase 0 Trials Murgo, A. J. et al. Clin Cancer Res 2008;14:3675-3682

  13. Types of Phase 0/Expl IND trials • Pharmacologically relevant doses • Micro-dose studies

  14. Various Goals of Phase 0/Expl IND trials Pharmacologically relevant doses • Explore mechanism of action in humans • MOA defined in non-clinical models can be observed in humans • Agent binds to or inhibits its alleged target • Refine a biomarker assay using human tumor tissue and/or surrogate tissue • Provide human PK-PD relationship data prior to definitive single-agent or combination Phase 1 testing • Select most promising candidate for further development • Evaluate human PD of two or more analogs directed at same target and possessing practically the same preclinical properties

  15. Various Goals of Phase 0/Expl IND trials(2) Micro-dose studies • Less than 1/100th of the dose calculated (based on animal data) to yield a pharmacologic effect (max dose of <100 micrograms (≤30 nanomoles, protein products) • Evaluate in humans an agent’s biodistribution, binding characteristics and target effects • Develop novel imaging probes • Evaluate human PK (e.g., bioavailability) to select most promising candidate for further development

  16. Phase 0 – Small Sample Size • Demonstration target modulation requires: • Precise and reproducible assay methods • Robust drug effect • Limited intra-patient variability • Limited inter-patient variability • Innovative, rational statistical designs

  17. Why conduct Phase 0 trials?

  18. Why drugs fail • Unfavorable PK currently plays less of a role compared to early 1990’s • Lack of efficacy continues to play a major role • Lack of predictive animal models Kola & Landis; Nat Rev Drug Disc 2004 Ma & Zemmel; Nat Rev Drug Disc 2002

  19. Phase 0 trials Can Improve Efficiency and Success of Subsequent Trials Informing subsequent trials • Establishing MOA and drug hits its target in human subjects • Refining target/biomarker PD analytical assay with human biopsy samples • Developing reliable SOP for human tissue acquisition, handling, and processing • Determining dose and time-course that yields desired target effect • Exploring PK-PD relationships • Approximation of safe, efficacious starting dose for studies in different populations and settings: • Use in otherwise healthy subjects • In combination with other drugs or radiation • Support limited sampling in subsequent trials

  20. Phase 0 trials Can Improve Efficiency and Success of Subsequent Trials (cont.) • Selecting a candidate agent with most favorable properties for further clinical testing • Eliminating “bad” agents early in clinical development because of poor PD or PK properties e.g., lack of target effect, poor bioavail., very rapid clearance “Fail fast, fail early”

  21. What Makes an Agent a Good Candidate for a Phase 0 PD Trial • Credentialed target (modulation yields desired effect) • Wide therapeutic window (e.g., biomodulators) • PD modulation expected at low doses and short duration of exposure (e.g. ≤7 days) • Drug target effect evaluable with a relatively small sample size (≤10-15 patients) • Robust drug effect • Precise analytical assay • Target expressed in majority of study subjects

  22. Suggested Reading • Kummar, S., et al. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. J Clin Oncol; 27:2705-11, 2009 • Kinders, R., et al. Phase 0 trials in cancer drug development. Mol Interventions; 7:327-34, 2007 • Jacobson-Kram D, Mills G. Leveraging exploratory investigational new drug studies to accelerate drug development. Clin Cancer Res;14:3670–4, 2008 • Murgo AJ, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res; 14:3675-82, 2008 • Doroshow, JH, Parchment, RE. Oncologic Phase 0 Trials: Incorporating Clinical Pharmacodynamics from Concept to Patient. Clin Cancer Res 14:3658-63, 2008 • Gutierrez, M, Collyar, D. Patient perspectives on phase 0 clinical trials. Clin Cancer Res 14:3689–91, 2008 • Abdoler E, et. al. The ethics of phase 0 oncology trials. Clin Cancer Res 2008;14:3692–7 • Kummar, S, et al. Compressing drug development timelines in oncology using phase ‘0’ trials. Nature Reviews Cancer 7:131-9, 2007 • Rubinstein, LV, et al. The Statistics of Phase 0 Trials. Statistics in Med; in press.

  23. Back-up Slides

  24. Phase 0 – Patient Recruitment and Ethical Considerations Challenging, but not insurmountable • Potential barriers to patient enrollment • No therapeutic intent or chance of benefit • Pre- and post-treatment tissue biopsies • Delay or exclusion from other trials or therapies External concerns about ethics and availability of patients for study • Institutional Ethics committee review and input • IRB approval • Informed Consent Process • Clearly explain the rationale for the study • Clearly describe the limited treatment and follow up period • Clearly state that there is absolutely no anticipated clinical benefit to the participant • More straightforward than Phase 1 – but low risk – avoid if possible – washout period for phase 0 shorter

  25. Statistical Methodology for Phase 0 Trials Murgo, A. J. et al. Clin Cancer Res 2008;14:3675-3682

  26. Murgo, A. J. et al. Clin Cancer Res 2008;14:3675-3682

More Related